Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEJ027 first-line afatinib in elderly EGFR-mutant NSCLC
jRCTs031180136Phase 2Completed
- Sponsor
- Not applicable
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Not applicable. Primary endpoint: Overall response rate. Started Jan 2016; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180136.